doc. MUDr. Daniela Žáčková, Ph.D.
Associate professor, Department of Internal Medicine, Hematology and Oncology
Correspondence Address:
Jihlavská 340/20, 625 00 Brno
Phone: | +420 532 23 2838, 3603 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 218
2013
-
Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications
American Journal of Hematology, year: 2013, volume: 88, edition: 9, DOI
-
Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
Leukemia & Lymphoma, year: 2013, volume: 54, edition: 10, DOI
-
Estimation of the Current Survival Survival Measures in Chronic Myeloid Leukemia: Metodology and New Software Tools.
Year: 2013, type: Conference abstract
-
Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.
Cancer Medicine, year: 2013, volume: 2, edition: 2, DOI
-
Chronická myeloidní leukemie
Postupy diagnostiky a léčby leukemií a jejich infekčních komplikací u dospělých pacientů : doporučení České leukemické skupiny - pro život (CELL) / editoři Michael Doubek a Jiří Mayer, year: 2013
-
Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia.
Haematologica, year: 2013, volume: 98, edition: 10, DOI
-
Mechanism of Impaired Glukose Metabolism during Nilotinib Therapy in Patients with Chronic Myelogenous Leukemia
Year: 2013, type: Conference abstract
-
Nuromuscular toxicity of tyrosine kinase inhibitors in the therapy of patients with chronic myeloid leukemia
Year: 2013, type: Conference abstract
-
Skin adverse effects of tyrosine kinase inhibitors in the therapy of patients with chronic myeloid leukemia - single centre experience
Year: 2013, type: Conference abstract
-
The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.
Leukemia & Lymphoma, year: 2013, volume: 54, edition: 9, DOI